1. Scrip
  2. >>Conferences
  3. >>BIO

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Acquisition Numbers Rise, Values Fall In Q1

 
• By Mandy Jackson

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Multiple stock graphs and numerical data overlaid on a cityscape, representing the finance and economy
Deals are happening, but they are not as large as in 2023 • Source: Shutterstock

Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.

Key Takeaways

  • Business development executives and investors at the BIO International Convention said that biopharma dealmaking activity in 2024 is robust despite shifts in focus for big pharma.

    ...

Biomedtracker reported 39 M&A deals totaling $37bn during the first quarter of 2024, an improvement in terms of the number of transactions but a decline in overall value versus Q1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from BIO

More from Conferences

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.